BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS
NCT04827719
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
38
Enrollment
OTHER
Sponsor class
Conditions
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Interventions
DRUG:
BST-236
Sponsor
Groupe Francophone des Myelodysplasies